Akcea Therapeutics (NASDAQ:AKCA) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
Several other equities analysts have also recently weighed in on the company. Cowen reiterated a “hold” rating on shares of Akcea Therapeutics in a research report on Sunday, September 2nd. Zacks Investment Research cut Akcea Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 31st. Stifel Nicolaus reduced their price target on Akcea Therapeutics from $33.00 to $25.00 and set a “hold” rating for the company in a research report on Tuesday, August 28th. UBS Group cut Akcea Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. Finally, BMO Capital Markets lifted their price target on Akcea Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $35.00.
Shares of NASDAQ AKCA opened at $27.23 on Friday. The firm has a market capitalization of $2.26 billion, a PE ratio of -12.16 and a beta of 0.37. Akcea Therapeutics has a fifty-two week low of $15.20 and a fifty-two week high of $40.75.
Akcea Therapeutics (NASDAQ:AKCA) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.04) by $0.32. The company had revenue of $18.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Akcea Therapeutics had a negative return on equity of 58.32% and a negative net margin of 192.97%. The firm’s quarterly revenue was up 221.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.41) earnings per share. analysts anticipate that Akcea Therapeutics will post -2.45 EPS for the current year.
Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new stake in Akcea Therapeutics during the first quarter valued at $104,000. Cubist Systematic Strategies LLC bought a new stake in Akcea Therapeutics during the first quarter valued at $201,000. Paloma Partners Management Co bought a new stake in Akcea Therapeutics during the second quarter valued at $216,000. Barclays PLC boosted its stake in Akcea Therapeutics by 375.7% during the first quarter. Barclays PLC now owns 11,312 shares of the company’s stock valued at $290,000 after buying an additional 8,934 shares during the period. Finally, Millennium Management LLC bought a new stake in Akcea Therapeutics during the first quarter valued at $310,000. 26.58% of the stock is owned by institutional investors.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.
Read More: Price to Earnings Ratio (PE)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.